Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Jul 20, 2010


Melina Cimler has been appointed as vice president of quality and regulatory affairs at Illumina. Prior to joining the company, she was president of PandiaDx Consulting, where she provided regulatory and compliance guidance for the development of in vitro diagnostics products and medical devices. Before that, she held several positions in quality, regulatory, and government affairs at Beckman Coulter, and senior quality and regulatory roles at Abbott Molecular and Gen-Probe. Cimler holds a PhD in pharmacology from the University of Washington.

Jacques Simard has become the chair of Genome Canada's science and industry advisory committee, which provides strategic advice on approaches and directions to the organization's board of directors. He is a professor in the department of molecular medicine at Laval University and director of the endocrinology and genomics axis at the Centre Hospitalier Universitaire de Québec Research Centre.

Harlan Robins, Christopher Carlson, and Chad Robins are the co-founders of Adapative TCR Technologies, a startup providing immune system repertoire profiling services (see story, this issue).

Harlan Robins is a faculty member in the computational biology group of the public health sciences and human biology divisions at the Fred Hutchinson Cancer Research Center. Previously, he was a postdoc with Arnold Levine at Princeton University, and before that, a postdoc in theoretical physics at the Weizmann Institute of Science in Israel. He holds a master's degree and a PhD in theoretical physics from the University of California, Berkeley, and a bachelor's degree in physics from Harvard University.

Carlson is a faculty member in epidemiology and computational biology at the Hutch. Before that, he was a postdoc with Debbie Nickerson at the University of Washington, and prior to that, he worked in DNA diagnostics at Roche Molecular Systems. He holds a PhD in genetics from Stanford University and an undergraduate degree in molecular biology from Pomona College.

Chad Robins is Adaptive TCR Technologies' president and CEO. Previously, he was chief operating officer at Connaught Real Estate Finance, a hedge fund, and vice president of operations at Pulte Homes. He holds an MBA from the Wharton School at the University of Pennsylvania and an undergraduate degree in entrepreneurship and business from Cornell University.

Jessica Andriesen is the company's vice president of operations. Previously, she was a project manager and program administrator at the Hutch. She holds a PhD in genetics from the University of Washington and an undergraduate degree in biological sciences from Cornell.

Robert Livingston is the firm's vice president of laboratory research and development. Previously, he was a senior research scientist and project manager of the Environmental Genome Project at the University of Washington department of genome sciences. Prior to that, he was a postdoc with Debbie Nickerson at the same institution. He holds a PhD in pathology from the University of Washington School of Medicine and an undergraduate degree in biochemistry from Texas A&M University.

Andris Zoltners is a member of the firm's board of directors. He is a marketing professor at the Kellogg School of Management at Northwestern University and the founder and chairman of management consulting firm ZS Associates. Zoltners holds a PhD from Carnegie-Mellon University.

Arnold Levine, Jerry Nepom, Jay Shendure, and Edus Warren are members of the company's scientific advisory board.

Levine is a professor of systems biology at the Institute for Advanced Study at Princeton and a professor of biochemistry and pediatrics at Robert Wood Johnson Medical School.

Nepom is the director of the Benaroya Research Institute at Virginia Mason and a professor at the department of immunology at the University of Washington School of Medicine. He holds an MD and a PhD in biochemistry from the University of Washington and a bachelor's degree from Harvard.

Shendure is an assistant professor in the department of genome sciences at the University of Washington. He holds an MD and a PhD from Harvard and an undergraduate degree from Princeton.

Edus Warren is an associate professor in the department of medicine at the University of Washington and an associate member in the program in immunology, clinical research division, at the Hutch.

Graham Allen, Matt Kahn, Peter Keane, Richard Mitchell, Josh Rosen, and Craig Weissman are members of the company's corporate advisory board.

Allen is the president and CEO of Sloan Valve Company. He holds a degree from the University of Colorado at Boulder.

Kahn is the executive vice president of LRP Publications, where he oversees the operations of the magazine division. He holds a BA in business management from Cornell.

Keane is the senior vice president of operations PMO at Pulte Homes. Prior to that, he worked in production and corporate accounting at Metro-Goldwyn-Mayer and in the audit group at KPMG Peat Marwick.

Mitchell is director of business development at the Hutch. Previously, he was director of strategic alliances at MDS Pharma Services and scientific director of marketing and business development at Nastech Pharmaceutical. He holds a PhD in microbiology from the University of Minnesota.

Rosen is a partner at Freshford Capital Management, a hedge fund. Prior to that, he was a partner at RLR Capital Partners, a hedge fund focused on small and mid-cap equities. He holds an MBA from Wharton and a BA from Penn.

Weissman is the chief technology officer of, an enterprise cloud computing company. He holds an MS in computer science and a BA in applied mathematics from Harvard.

Human genome analysis firm Omicia recently released information about its executives and advisors (IS 7/13/2010).

Martin Reese is the company's co-founder, CEO, and board chairman. Prior to founding Omicia in 2002, he was vice president of discovery informatics at ValiGen. Previously, he founded bioinformatics firm Neomorphic, which Affymetrix acquired in 2000. Reese holds a PhD in genetics, jointly awarded by the University of California, Berkeley, and the University of Hohenheim in Germany, and a master's degree in medical informatics from the University of Heidelberg.

Edward Kiruluta is Omicia's co-founder and chief technology officer. Until earlier this year, he was vice president of development at Symyx Technologies. Prior to that, he was vice president of engineering at DemandTec, and before that, senior director of informatics at Merck Research Labs. Previously, he was chief technology officer at DoubleTwist, formerly Pangea Systems. Kiruluta studied electrical engineering at Memorial University in Canada.

Paul Billings is a co-founder of Omicia and a member of its board. He is the founding and acting director and chief scientific officer of the Genomic Medicine Institute at El Camino Hospital in Mountain View, Calif. Prior to that, he was president, CEO, and director of CELLective Dx, prior to its merger with Exalan. In addition, he was executive chairman of Signature Genomics Laboratories. Until 2007, he was senior vice president and senior geneticist at Laboratory Corporation of America. Before that, he was deputy chief of staff and chief of general internal medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then chief medical officer and deputy network director of VISN 17 in the Department of Veterans Affairs. Billings holds MD and PhD degrees from Harvard University and an AB from the University of California, San Diego.

John Stuelpnagel is a company co-founder and advisor to its board of directors. He is also a co-founder of Illumina, where he held various titles, including acting president and CEO, vice president of business development, senior vice president of operations, chief operating officer, and general manager of the microarray business. Previously, he was an associate with venture capital firms CW Group and Catalyst Partners. Stuelpnagel holds a doctorate in veterinary medicine and a BS in biochemistry from the University of California, Davis, and an MBA from the University of California, Los Angeles.

Michael Ashburner, Pui-Yan Kwok, George Miklos, James Scott, Terry Speed, and John Witte are members of Omicia's scientific and medical advisory board.

Ashburner is a professor of genetics at Cambridge University and a former senior scientist at the European Molecular Biology Laboratory.

Kwok is a professor of cardiovascular genetics at the Cardiovascular Research Institute at the University of California, San Francisco. Prior to that, he was a professor at the Washington University School of Medicine.

Miklos is director of Secure Genetics and chief scientific officer of Human Genetic Signatures. Previously, he was a group leader at the Research School of Biological Sciences at the Australian National University.

Scott is head of genomic cardiology at Imperial College London. Previously, he was chief of academic medicine and of NHS clinical service, chief of cardiology, and head of molecular medicine at the Royal Postgraduate Medical School, Hammersmith Hospital. He is the founder and first head of the Institute of Genetics and Genomics and founder of the Bioinformatics Centre at Imperial College London. In the past, he worked at the UCSF Medical Center.

Speed is a professor of statistics at UC Berkeley and head of the bioinformatics division at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia.

Witte is a professor of epidemiology at UCSF. Previously, he was at Case Western Reserve University School of Medicine, and before that, an assistant professor of preventive medicine at the University of Southern California.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.